AMPLY Discovery
Techstars '23Belfast, GB · Founded 2022 · 7 employees on LinkedIn · 4 known investors
AMPLY Discovery is a UK-based biotech company that uses AI and computational biology to identify therapeutic targets in non-coding regions of the genome and develop first-in-class drugs through an integrated discovery platform combining machine learning with wet-lab validation. The company is developing therapeutics for oncology and drug-resistant infectious diseases, particularly antimicrobial-peptide and long non-coding RNA oligonucleotide programmes.
Founders & leadership
Investors · 4
Funding
SEC filings, press & company announcements- Undisclosed amountSeedMay 2025Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Companies House · registry record
View on Companies House ↗- Registered name
- AMPLY DISCOVERY LIMITED
- Company number
- NI676691
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 19 Feb 2021
- Registered office
- C/O Qubis Ltd, 63 University Road, Belfast, BT7 1NF
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 28 Feb 2026 · next due 30 Nov 2027
- Confirmation statement
- last made up to 6 Mar 2026 · next due 20 Mar 2027
Current officers · 5
- Mark Granville Beards — director, appointed 24 Feb 2023
- Christopher James Creevey — director, appointed 19 Feb 2021
- Anne Elizabeth Dornan — director, appointed 19 Feb 2021
- Benjamin James Thomas — director, appointed 19 Feb 2021
- Dermot Tierney — director, appointed 19 Feb 2021
Source: Companies House public register · retrieved 24 Jul 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does AMPLY Discovery do?
- AMPLY Discovery is a UK-based biotech company that uses AI and computational biology to identify therapeutic targets in non-coding regions of the genome and develop first-in-class drugs through an integrated discovery platform combining machine learning with wet-lab validation. The company is developing therapeutics for oncology and drug-resistant infectious diseases, particularly antimicrobial-peptide and long non-coding RNA oligonucleotide programmes.
- Who are AMPLY Discovery's investors?
- AMPLY Discovery's investors include Clarendon Fund Managers Ltd., Techstars, Twin Path Ventures, QUBIS.
- Where is AMPLY Discovery headquartered?
- AMPLY Discovery is headquartered in Belfast, GB.